Clinical Trial Update: Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating increasing doses of DaxibotulinumtoxinA for Injection (DAXI) for moderate to severe lateral canthal lines; results completed with data …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lateral Canthal Lines

Drugs mentioned

• DaxibotulinumtoxinA for Injection (DAXI for Injection) (daxibotulinumtoxinA)

Snippet

Sponsor: Revance Therapeutics, Inc. | Conditions: Lateral Canthal Lines | Phase 2 | Status: COMPLETED | Results posted: 2023-06-27